|
|
Congratulations, Martine Elias! | |
Martine Elias, Chief Executive Officer | |
|
Dear Myeloma Canada community,
It is with great joy and pleasure that we announce the advancement of our well-regarded Executive Director, Martine Elias, to the distinguished position of CEO at Myeloma Canada.
Martine has been the driving force behind numerous achievements and advancements that have shaped Myeloma Canada into the leading organization it is today. The decision to appoint Martine to this critical role reflects her outstanding contributions and leadership.
| |
Accomplishments and growth
| |
Patient programs: Martine has played a pivotal role in developing and implementing innovative patient programs that have provided support to individuals facing multiple myeloma. Her commitment to enhancing the lives of patients has been unwavering, resulting in tangible improvements to patients’ well-being. | | |
Research strategy: Through strategic vision and effective collaboration, Martine has elevated Myeloma Canada's role in advancing multiple myeloma research. Her dedication to fostering collaborations advancing research projects has positioned the organization as a key player in the pursuit of improved treatments and, ultimately, a cure. | | |
Elevating Myeloma Canada leadership: Myeloma Canada, under Martine's leadership, has become the go-to resource for individuals navigating the challenges of a myeloma diagnosis. | |
| |
The recent accreditation of Myeloma Canada by Imagine Canada signifies a commitment to excellence in governance, transparency, and ethical fundraising practices, enhancing an organization's credibility and trustworthiness within the charitable sector. The organization's reputation at home and on the international stage as a reliable and empathetic ally throughout the myeloma journey is a testament to Martine's tireless efforts to build a strong, passionate and empowered team. | |
Myeloma Canada Team, 2023 | | |
Martine's remarkable journey | |
Quebec awareness and legislative day, 2019 | |
Martine has been an invaluable leader and advocate within the myeloma community, serving as the Executive Director of Myeloma Canada since June 2018. In this role, she has tirelessly worked to bring the Canadian myeloma community together, fostering a strong, unified national voice for those living with multiple myeloma. | |
In addition to her role at Myeloma Canada, Martine has been a trailblazer in various national and international initiatives. | |
|
As the Co-Chair of the Collective Oncology Network for Exchange (CONECTed), she has played a crucial role in promoting education and understanding of cancer therapies and to drive health policies to ensure equal, equitable and timely access for all Canadians. | |
Martine's commitment to patient-centered approaches is further demonstrated through her involvement in the founding steering committee of the Patient-Centered Approach to Clinical Trials (PACT). This initiative works towards active and equal patient engagement in cancer clinical trials, highlighting Martine's dedication to ensuring the patient voice is heard in every aspect of cancer research. | |
Advocacy for Real-World Evidence | |
|
In recent years, Martine has emerged as a strong advocate for the use of
Real-World Evidence and evidence-based generation research. She firmly believes in the importance of the patient voice shaping the evolving data landscape, particularly when it comes to making crucial decisions about accessing promising therapies.
| | |
Global Myeloma Action Network Summit 2023 | |
International leadership: Martine's leadership extends globally. She was invited to join the International Myeloma Foundation Board of Directors in February 2020, where she currently serves on the International Advocacy Committee and the Governance Committee. Martine also represents Canada on the Myeloma Patient Europe Community Advisory Board (CAB), addressing key challenges faced by patients at an international level. | | |
Martine's career journey began in clinical research in the pharmaceutical industry. Over the years, she has dedicated herself to patient advocacy, empowering the patient voice, and ensuring access to essential medical treatments. Her previous roles, including Director of Access, Advocacy, and Community Relations at Myeloma Canada, National Director of Community Relations at Janssen Inc., and Market Access and Health Economics Team Leader at GSK, showcase her extensive experience and expertise. | |
Myeloma Canada Scientific Roundtable, 2016 | |
Vision for Myeloma Canada | |
Martine brings a wealth of experience, passion, and a clear vision for the future of Myeloma Canada. Her collaboration and commitment to evolving myeloma knowledge for the betterment of patients will undoubtedly lead us to new heights. | | |
|
Please join us in congratulating Martine Elias on this well-deserved appointment. We look forward to the continued growth and success of Myeloma Canada under her exemplary leadership.
Sincerely,
Mélanie Martel, Chair of the Board
William Paine, Vice-Chair of the Board
| |
Montreal Multiple Myeloma March, 2022 | |
Myeloma Canada's promise: To improve the lives and empower all Canadians affected by myeloma, accelerate access to the best care, while supporting the pursuit of its cure and prevention. | |
Follow us on social media for the most up-to-date information and resources: | |
Si vous préférez recevoir vos communications en français, écrivez-nous à contact@myelome.ca. | |
|
Your donation enables us to better serve the myeloma community.
Thank you for your continued faith in all that we do.
| | | | |
